32 results about "Activation lymphocyte" patented technology

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose.

The invention discloses lymphocyte antigen epitope peptides and application thereof, belongs to the fields of medical immunology and infectious diseases, and particularly relates to 164 thymus dependent lymphocyte antigen epitope peptides of five proteins of SARS-CoV-2 and application thereof. The antigen epitope peptides can be presented by HLA-A molecules to stimulate activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted. The antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection, and have a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention provides a kit for detecting human regulatory T cell subtypes and a detection method and belongs to the technical field of cell subtype detection. The provided kit comprises components as follows: a blood diluent, a mononuclear cell separation medium, a cell culture fluid, a lymphocyte activation solution, dead cell removal dyes, an FcR blocking agent, a fluorescence labeled antibodyresisting human cell surface labeling molecules, a fluorescence labeled antibody resisting human intracellular molecules, a PBS buffer solution, lipopolysaccharide, a washing buffer solution, a celldyeing buffer solution, a cell fixing solution and a permeable membrane lotion. During detection, firstly, mononuclear cells in whole blood are separated, then, mononuclear cells of human peripheral blood are stimulated, finally, a fluorescent antibody is stained, and the regulatory T cell subtypes can be detected. By use of the kit and the detection method, 2-6 regulatory T cell subtypes can be simply and rapidly distinguished.

The invention relates to peptides having an amino acid sequence substantially homologous to an amino sequence of a domain of a pyrogenic exotoxin, which domain forms a central turn in the exotoxin starting within β-strand 7 and connecting the β-strand 7, via short β-strand 8, to α-helix 4, and ending within α-helix 4, based on the domain numbering of Staphylococus aureus enterotoxin B. The peptides of the invention are capable of antagonizing toxin-mediated activation of T-lymphocytes, do not have agonist activity, and are capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. The invention also relates to broad spectrum pharmaceutical compositions for the treatment, protection against or short term prophylaxis of toxin-mediated activation of T cells, comprising as active ingredient at least one peptide according to the invention or a derivative thereof, and to broad spectrum vaccines for conferring long term immunity against toxic shock induced by at least one pyrogenic exotoxin.

The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.

The invention discloses combination measuring, and discloses a method used for measuring the MHC II combination activity of Lymphocyte activationgene-3(LAG-3) protein, or fragments, derivatives, or analogues of Lymphocyte activationgene-3(LAG-3) protein. The method comprises measuring of the LAG-3 protein, the fragments, the derivatives, or the analogues using biolayer interferometry (BLI). The method can be used for quality control measuring of the compounds in good manufacturing practice (GMP) grade production. The invention also discloses a probe and a kit of the method.

The invention provides a thiophene[3,2-d]pyrimidine compound as shown in a structural formula I as well as a preparation method and application thereof. The compound or pharmaceutically acceptable salt has remarkable inhibition effect on Bruton tyrosine kinase (BTK), has high BTK inhibition activity and high kinase selectivity, and has strong immunosuppressive activity effect. The compound or pharmaceutically acceptable salt has low cytotoxicity on mouse primary lymphocytes, has remarkable inhibition activity on lipopolysaccharide (LPS)-induced B lymphocyte activation and proliferation, has alarge administration window and high safety, and can be widely applied in the field of treatment of inflammation, immune system diseases and malignant tumor. (The formula is as shown in the description).

The invention relates to a chimeric nucleic acid molecule used for immunoregulation, and application of the chimeric nucleic acid molecule. Specifically, the chimeric nucleic acid molecule comprises aoligonucleotide with a CpG motif and an aptamer capable of resisting a lymphocyte activationgene 3 (LAG-3), a synergetic effect capable of activating toll-like receptor 9 (TLR9) can be generated, thechimeric nucleic acid molecule can be used to initiate systemic immune responses, and a disease treatment effect is improved.

The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors and serve as a base for the preparation of therapeutic compositions for the prophylactics and treatment of human diseases associated with T-lymphocyte activation, including, but not limited to, autoimmune diseases, inflammation and allergy or transplant rejections. In addition, said peptides and the associated biological and genetic material can form useful tools for the development of tests that can be used to find compounds that have a selective antagonist activity in relation to CN.

Nucleic acid aptamers capable of binding to lymphocyte activation gene 3 (LAG-3) and uses thereof for modulating immune responses. Such aptamers may comprise a G-rich motif, for example, GX₁GGGX₂GGTX₃A (SEQ ID No: 1), in which each of X₁ and X₂ are independently G, C, or absent, and X₃ is T or C, or L-(G)_n-L′, in which n is an integer of 5-9 inclusive, and L and L′ are nucleotide segments having complementary sequences. Also provided herein are multimeric nucleic acid aptamers containing a backbone moiety, which comprises a palindromic sequence.

The invention belongs to the technical field of gene science and technology, and particularly relates to a method for researching activation and differentiation of B lymphocytes by an interferon-induced gene IFIT3, which comprises the following steps: step 1, collecting peripheral blood of clinically diagnosed SLE patients and healthy control persons, extracting peripheral blood mononuclear cells (PBMC) by Ficoll, and separating and purifying B cells by adopting immunomagnetic beads; step 2, culturing an in-vitro induced hair growth center B cell (iGCB), and detecting the change condition of an IFIT3 transcript by a fluorescent quantitative PCR (qRTPCR) technology; 3, overexpressing IFIT3 through an iGCB system, inducing and differentiating into plasma cells (iPC), and detecting main regulatory factors IRF4, Pax5 and Bcl6 for differentiating the B cells into the plasma cells through flow analysis; and 4, exploring epigenetic modification of the IFIT3 protein by using technologies such as mass spectrum, co-immunolocalization, Western-blot, molecular cloning and the like, and discussing the influence of the interferon-induced gene IFIT3 on activation and differentiation functions of B lymphocytes, thereby providing a scientific basis for clarifying the pathogenesis of lupus and finding targets for treating lupus in the future.

The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.

The invention discloses a method and a kit for mixed lymphocyte co-culture test detection. The method and the kit can be used for the mixed lymphocyte co-culture test detection, and are applicable to tissue matching test before organ transplantation, immunologic function test on a low-immunity patient, immunological rejection detection on drugs and transplants, influence detection on T lymphocyte activation caused by other cells or external stimulants, screening of drugs for influencing T cell activation capacity, and other immunoregulation test research. The method and the kit are mainly based on flow cytometry, need a small number of samples, and are easy to operate, high in operability, high in accuracy, high in repeatability, clear in detection result, high in specificity, easy to analyze, low in cost and strong in generalization performance.